Therefore, given that the design of clinical trials evaluating the development of non-AIDS comorbidities according to the ART strategy is unlikely, evaluation of the effect of therapies on surrogate markers, such as the CD4/CD8 ratio, is justified. Here, CD8A is linked to AIDS.